Incyte's mission is to provide its customers with DNA sequence information. This is used as a basis for target discovery and evaluation. The number of companies making use of this resource has increased rapidly over the past six years. In terms of company value, Incyte's greatest asset are its gene sequences, yet few of these have been published and several are in the patent pipeline. In the long term, both the opinion of the USPTO and Incyte's own ability to file full length cDNAs before its competition will be critical to the Company's success.